ASSESSMENT OF PATIENT'S RADIATION EXPOSURES RESULTED FROM PET/CT 18F-FCH AND 68GA-PSMA PROCEDURES.

This study has sought to evaluate patient exposures during the course of particular diagnostic positron emission tomography and computed tomography (PET/CT) techniques. A total of 73 patients were examined using two types of radiopharmaceutical: ¹⁸F-fluorocholine (FCH, 48 patients) and ⁶⁸Ga-prostate-specific membrane antigen (PSMA, 25 patients). The mean and range of administered activity (AA) in MBq, and effective dose (mSv) for FCH were 314.4 ± 61.6 (462.5–216.8) and 5.9 ± 1.2 (8.8–4.11), respectively. Quoted in the same set of units, the mean and range of AA and effective dose for ⁶⁸Ga-PSMA were 179.3 ± 92.3 (603.1–115.1) and 17.9 ± 9.2 (60.3–11.5). Patient effective doses from ¹⁸F-FCH being a factor of two greater than the dose resulting from ⁶⁸Ga-PSMA PET/CT procedures. CT accounts for some 84 and 23% for 18F-FCH and ⁶⁸Ga-PSMA procedures, accordingly CT acquisition parameter optimization is recommended. Patient doses have been found to be slightly greater than previous studies. [ABSTRACT FROM AUTHOR]